Organogenesis (NASDAQ:ORGO) Trading Up 1.7% - Time to Buy?

Key Points

• Organogenesis (ORGO) climbed 1.7% to $2.39 on Monday with ~1.11M shares traded, roughly 50% below its average volume, and the stock remains below its 50‑day ($2.73) and 200‑day ($3.95) moving averages.
• Analysts have recently upgraded the name (two Buys, one Hold), with a MarketBeat consensus of “Moderate Buy” and an average price target of $8.50.
• The company reported a quarterbeat — $0.31 EPS vs. $0.21 expected and $225.6M in revenue vs. $172.7M expected — and a director bought 10,000 shares, while insiders own about 33% of the stock.

Organogenesis (NASDAQ:ORGO - Get Free Report) shot up 1.7% on Monday . The company traded as high as $2.46 and last traded at $2.39. 1,113,586 shares traded hands during trading, a decline of 50% from the average session volume of 2,232,015 shares. The stock had previously closed at $2.35.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ORGO shares. BTIG Research reaffirmed a "buy" rating and issued a $8.00 price target on shares of Organogenesis in a research note on Thursday, March 26th. Weiss Ratings raised Organogenesis from a "sell (d+)" rating to a "hold (c)" rating in a research report on Friday, February 27th. Finally, Wall Street Zen upgraded shares of Organogenesis from a "hold" rating to a "buy" rating in a research note on Sunday, March 8th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Organogenesis has an average rating of "Moderate Buy" and an average target price of $8.50.

Organogenesis Stock Performance

The stock's 50-day moving average price is $2.73 and its 200-day moving average price is $3.95. The company has a market cap of $307.45 million, a P/E ratio of 29.88 and a beta of 1.48. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.62 and a quick ratio of 3.32.

Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.21 by $0.10. Organogenesis had a net margin of 5.32% and a return on equity of 21.41%. The company had revenue of $225.61 million for the quarter, compared to analysts' expectations of $172.68 million.

Insider Transactions at Organogenesis

In other news, Director Michael Joseph Driscoll bought 10,000 shares of the firm's stock in a transaction on Monday, March 9th. The shares were purchased at an average cost of $2.67 per share, with a total value of $26,700.00. Following the acquisition, the director directly owned 225,707 shares in the company, valued at $602,637.69. This represents a 4.64% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 33.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Organogenesis

Hedge funds and other institutional investors have recently modified their holdings of the business. Creative Planning grew its holdings in shares of Organogenesis by 8.2% during the 3rd quarter. Creative Planning now owns 38,279 shares of the company's stock valued at $162,000 after purchasing an additional 2,887 shares during the last quarter. Federated Hermes Inc. lifted its holdings in shares of Organogenesis by 52.8% during the fourth quarter. Federated Hermes Inc. now owns 8,541 shares of the company's stock worth $44,000 after purchasing an additional 2,953 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Organogenesis by 10.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 40,278 shares of the company's stock worth $209,000 after purchasing an additional 3,825 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Organogenesis by 57.0% in the third quarter. BNP Paribas Financial Markets now owns 14,522 shares of the company's stock worth $61,000 after purchasing an additional 5,273 shares during the last quarter. Finally, Quarry LP acquired a new stake in Organogenesis in the third quarter valued at $25,000. Institutional investors own 49.57% of the company's stock.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company's product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.